Cardiac fibroblasts: contributory role in septic cardiac dysfunction

Area of Science:

• Cardiovascular Biology
• Sepsis Pathophysiology
• Fibrosis Research

Background:

• Sepsis-associated cardiac dysfunction is a major cause of mortality.
• The exact mechanisms driving sepsis-induced heart problems remain largely unknown.
• Cardiac fibroblasts' role as potential disease modifiers in sepsis is under investigation.

Observation:

• Lipopolysaccharide (LPS) stimulation of human cardiac fibroblasts (HCFs) in vitro upregulated pro-inflammatory molecules and matrix metalloproteinase-9 (MMP-9) expression and activity.
• LPS-induced α-smooth muscle actin expression in HCFs was dependent on MMP-9.
• Septic mice exhibited elevated pro-inflammatory cytokines and MMP-9 in heart tissue, alongside cardiac fibrosis and dysfunction.

Findings:

• Cardiac fibroblasts are activated by lipopolysaccharide (LPS), releasing inflammatory mediators and MMP-9.
• MMP-9 plays a key role in LPS-induced changes in cardiac fibroblasts, including α-smooth muscle actin expression.
• Sepsis induces cardiac inflammation, fibrosis, and dysfunction in mice, associated with increased cardiac MMP-9 and inflammatory markers.

Implications:

• Cardiac fibroblasts are implicated in the pathogenesis of sepsis-induced heart dysfunction.
• Targeting MMP-9 may offer a therapeutic strategy to ameliorate cardiac dysfunction during sepsis.
• Understanding fibroblast roles is crucial for improving outcomes in sepsis patients.